Gianluca Masi

Summary

Country: Italy

Publications

  1. ncbi request reprint First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
    G Masi
    Division of Medical Oncology, Department of Oncology, Livorno, Italy
    Ann Oncol 17:1249-54. 2006
  2. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
  3. ncbi request reprint Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
    Gianluca Masi
    Unità Operativa Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Lancet Oncol 11:845-52. 2010
  4. doi request reprint Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Gianluca Masi
    Department of Oncology, Azienda USL 6 of Livorno, Istituto Toscano Tumori, Livorno, Italy
    Clin Colorectal Cancer 7:7-14. 2008
  5. ncbi request reprint Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine
    Gianluca Masi
    UO Oncologia Medica 2 Universitaria, Ospedale Santa Chiara, Pisa, Italy
    Nat Rev Clin Oncol 6:670-4. 2009
  6. ncbi request reprint Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer
    Gianluca Masi
    Department of Oncology, Division of Medical Oncology, Presidio Ospedaliero, Viale Alfieri 36, Livorno, 57124, Italy
    Ann Surg Oncol 13:58-65. 2006
  7. ncbi request reprint A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed
    Gianluca Masi
    Department of Oncology, Civil Hospital, Livorno, Italy
    Clin Cancer Res 10:1657-63. 2004
  8. doi request reprint Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches
    Gianluca Masi
    U O Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy
    Future Oncol 7:1299-323. 2011
  9. doi request reprint Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen
    Lorenzo Fornaro
    U O Oncologia Medica 2 Universitaria, Polo Oncologico Area Vasta Nord Ovest, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Clin Colorectal Cancer 11:71-6. 2012
  10. ncbi request reprint Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer
    Alfredo Falcone
    Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy
    J Clin Oncol 20:4006-14. 2002

Collaborators

Detail Information

Publications35

  1. ncbi request reprint First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
    G Masi
    Division of Medical Oncology, Department of Oncology, Livorno, Italy
    Ann Oncol 17:1249-54. 2006
    ..Therefore, we conducted the present analysis to evaluate the outcome of second-line treatments in these 74 patients...
  2. pmc Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
    Mario Scartozzi
    Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
    BMC Cancer 9:303. 2009
    ..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
  3. ncbi request reprint Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
    Gianluca Masi
    Unità Operativa Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Lancet Oncol 11:845-52. 2010
    ..We therefore assessed the safety and activity of the combination of FOLFOXIRI plus bevacizumab in patients with colorectal cancer...
  4. doi request reprint Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
    Gianluca Masi
    Department of Oncology, Azienda USL 6 of Livorno, Istituto Toscano Tumori, Livorno, Italy
    Clin Colorectal Cancer 7:7-14. 2008
    ....
  5. ncbi request reprint Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine
    Gianluca Masi
    UO Oncologia Medica 2 Universitaria, Ospedale Santa Chiara, Pisa, Italy
    Nat Rev Clin Oncol 6:670-4. 2009
    ..She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective...
  6. ncbi request reprint Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer
    Gianluca Masi
    Department of Oncology, Division of Medical Oncology, Presidio Ospedaliero, Viale Alfieri 36, Livorno, 57124, Italy
    Ann Surg Oncol 13:58-65. 2006
    ..The prognosis of unresectable metastatic colorectal cancer might be improved if a radical surgical resection of metastases could be performed after a response to chemotherapy...
  7. ncbi request reprint A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed
    Gianluca Masi
    Department of Oncology, Civil Hospital, Livorno, Italy
    Clin Cancer Res 10:1657-63. 2004
    ....
  8. doi request reprint Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches
    Gianluca Masi
    U O Oncologia Medica Universitaria, Azienda Ospedaliero Universitaria Pisana, Via Roma 67, 56126 Pisa, Italy
    Future Oncol 7:1299-323. 2011
    ..The multidisciplinary evaluation from the onset and during treatment remains the key element to maximizing the benefit of more intensive treatment modalities...
  9. doi request reprint Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen
    Lorenzo Fornaro
    U O Oncologia Medica 2 Universitaria, Polo Oncologico Area Vasta Nord Ovest, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
    Clin Colorectal Cancer 11:71-6. 2012
    ..We evaluated the outcome of second-line treatments among 196 patients treated with first-line FOLFOXIRI in three consecutive trials conducted by the Gruppo Oncologico Nord Ovest group...
  10. ncbi request reprint Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer
    Alfredo Falcone
    Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy
    J Clin Oncol 20:4006-14. 2002
    ....
  11. ncbi request reprint Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases
    Gianluca Masi
    Unità Operativa Oncologia Medica, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    Ann Surg 249:420-5. 2009
    ..The objective of this study was to evaluate the long-term outcome of resected patients and the impact of FOLFOXIRI on perioperative morbidities, mortality, and chemotherapy induced hepatotoxicity...
  12. pmc Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
    Fotios Loupakis
    U, O, Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Dipartimento di Oncologia, dei Trapianti e delle Nuove Tecnologie in Medicina, Universita di Pisa, Italy
    BMC Cancer 11:247. 2011
    ..Molecular predictors of bevacizumab efficacy in colorectal cancer have not been identified yet. Specific VEGF polymorphisms may affect gene transcription and therefore indirectly influence the efficacy of bevacizumab...
  13. doi request reprint Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis
    Gianluca Masi
    U O Oncologia Medica 2 Universitaria Polo Oncologico, Azienda Ospedaliero Universitaria Pisana, Via Roma, 67 56126 Pisa, Italy
    J Natl Cancer Inst 103:21-30. 2011
    ....
  14. ncbi request reprint Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients
    Fotios Loupakis
    Division of Medical Oncology, Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Italy
    Curr Cancer Drug Targets 10:37-45. 2010
    ..This review aims at resuming the state-of-the-art about the role of VEGF pathway inhibitors in the treatment of mCRC and at focusing on the present knowledge about candidate biomarkers as predictors of activity and toxicity...
  15. doi request reprint Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status
    Lorenzo Fornaro
    U O Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Crit Rev Oncol Hematol 78:243-51. 2011
    ..Scarce data are available about safety and efficacy of cetuximab in elderly metastatic colorectal cancer (mCRC) patients...
  16. ncbi request reprint Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori and Department of Oncology, Transplants and New Technologies in Medicine, University of Pisa, Via Roma, 67, 56126, Pisa, Italy
    Cancer Chemother Pharmacol 66:559-66. 2010
    ..We aimed to evaluate the activity and the safety profile of sequential chemotherapy with 5-FU-based doublets with C, Ir and D in the first-line treatment of AGC...
  17. ncbi request reprint Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation
    Giacomo Allegrini
    U O Oncologia Medica, Presidio Ospedaliero, Viale Alfieri 36, 57124, Livorno, and Division of Pharmacology and Chemotherapy, Department of Internal Medicine, University of Pisa, Italy
    Cancer Chemother Pharmacol 58:585-93. 2006
    ..The main purpose of this study was to investigate possible interactions between CPT-11 pharmacokinetics and thalidomide to explain the previously described gastrointestinal toxicity reduction...
  18. doi request reprint PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    J Clin Oncol 27:2622-9. 2009
    ..This retrospective study investigated the role of PTEN loss, AKT phosphorylation, and KRAS mutations on the activity of cetuximab plus irinotecan in patients with metastatic colorectal cancer (mCRC)...
  19. ncbi request reprint Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Alfredo Falcone
    U O Oncologia Medica, Istituto Toscano Tumori, Livorno, Italy
    J Clin Oncol 25:1670-6. 2007
    ....
  20. doi request reprint High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
    Daniele Santini
    Department of Oncology, University Campus Bio Medico, Rome, Italy
    Oncologist 13:1270-5. 2008
    ..Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases...
  21. ncbi request reprint 5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients
    Giacomo Allegrini
    Division of Medical Oncology, Department of Oncology, Civil Hospital, Livorno, Italy
    Am J Clin Oncol 27:101-5. 2004
    ..9 and 9.8 months, respectively. In conclusion, this regimen is feasible in an outpatient setting with acceptable and manageable toxicities, and it is associated with promising antitumor activity, time to progression, and survival...
  22. doi request reprint Palliative treatment of unresectable metastatic colorectal cancer
    Lorenzo Fornaro
    Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Medical Oncology Unit 2, Italy
    Expert Opin Pharmacother 11:63-77. 2010
    ....
  23. doi request reprint Anti-HER agents in gastric cancer: from bench to bedside
    Lorenzo Fornaro
    UO Oncologia Medica 2 Universitaria, Azienda Ospedaliero Universitaria Pisana, Istituto Toscano Tumori, Via Roma 67, 56126 Pisa, Italy lorenzo fornaro gmail com
    Nat Rev Gastroenterol Hepatol 8:369-83. 2011
    ..Refining patient selection is essential to maximize the benefit of targeted agents, to avoid significant toxicities and for the development of alternative therapeutic approaches in patients who have nonresponsive disease...
  24. doi request reprint Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer
    Fotios Loupakis
    University of Pisa, Department of Oncology, Transplants and New Technologies in Medicine, Pisa, Italy
    Expert Opin Biol Ther 11:519-31. 2011
    ..Nowadays, treatment options range from monotherapies with biologics or traditional chemotherapeutic agents to intensive combinations of chemotherapy plus targeted drugs...
  25. pmc Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review
    Lorenzo Fornaro
    Lorenzo Fornaro, Virginia Rotella, Editta Baldini, Division of Medical Oncology, Azienda USL2 Lucca, 55100 Lucca, Italy
    World J Gastroenterol 20:6081-91. 2014
    ....
  26. doi request reprint First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
    Fotios Loupakis
    Department of Oncology, Azienda USL 6, Istituto Toscano Tumori, Livorno, Italy
    Curr Opin Oncol 20:459-65. 2008
    ..This review focuses on what should be considered to define the optimal approach to each patient, in particular with regard to the intensiveness of first-line chemotherapy...
  27. ncbi request reprint EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
    Fotios Loupakis
    Azienda USL 6 Livorno, Division of Medical Oncology, Viale Alfieri 36, 57100 Livorno, Italy
    Pharmacogenomics 9:55-69. 2008
    ..Moving from clinical data suggesting that there could be a subpopulation of CRC patients that are more liable to benefit from anti-EGFR monoclonal antibodies, here we review major studies on determinants of outcome in this field...
  28. ncbi request reprint Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Irene Bargellini
    Department of Diagnostic and Interventional Radiology, Pisa University Hospital, Pisa, Italy
    Oncology 86:191-8. 2014
    ..1, European Association for the Study of the Liver (EASL), modified RECIST (mRECIST), tumor density and volume variations - in the early follow-up of SO treatment...
  29. pmc Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
    Giacomo Allegrini
    Division of Medical Oncology, Pontedera, Pisa, Italy
    Angiogenesis 15:275-86. 2012
    ..To evaluate UFT and cyclophosphamide (CTX) based metronomic chemotherapy plus celecoxib (CXB) for the treatment of patients with heavily pre-treated advanced gastrointestinal malignancies...
  30. doi request reprint Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
    Francesco Graziano
    Medical Oncology Unit, Hospital of Pesaro, Pesaro, Italy
    J Clin Oncol 26:1427-34. 2008
    ..We investigated possible associations between genetic variants and clinical outcomes of MCRC patients treated with cetuximab-irinotecan salvage therapy...
  31. doi request reprint Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy
    Lorenzo Fornaro
    Division of Medical Oncology, Ospedale Campo di Marte, Azienda USL2 Lucca, Lucca, Italy
    Future Oncol 10:285-304. 2014
    ..At the same time, identifying clinical and biological factors, which may help selecting patients with higher chances of benefit, is essential in order to hasten drug development and maximize treatment efficacy...
  32. ncbi request reprint Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
    Annamaria Ruzzo
    Institute of Biochemistry G Fornaini, University of Urbino, Urbino, Italy
    J Clin Oncol 25:1247-54. 2007
    ....
  33. ncbi request reprint Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer
    Mario Scartozzi
    Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
    Tumori 92:384-8. 2006
    ..We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy...
  34. ncbi request reprint Planning genetic studies on primary adult-onset dystonia: sample size estimates based on examination of first-degree relatives
    Giovanni Defazio
    Department of Neurologic and Psychiatric Sciences, University of Bari, Bari, Italy
    J Neurol Sci 251:29-34. 2006
    ..These sample size estimates suggest that the S-TDT may be feasible, whereas collection of cases for both TDT and ASP approaches would represent a major collaborative challenge...
  35. ncbi request reprint Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity
    Fotios Loupakis
    J Clin Oncol 25:1816-8. 2007